doravirine/islatravir (MK-8591A) / Merck (MSD)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
doravirine/islatravir (MK-8591A) / Merck (MSD)
MK-8591A-018, NCT04223791 / 2019-000587-23: Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Active, not recruiting
3
643
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL, Placebo to MK-8591A
Merck Sharp & Dohme LLC
HIV Infection
08/21
02/25
MK-8591A-017, NCT04223778 / 2019-000586-20: Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1

Active, not recruiting
3
672
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, ART
Merck Sharp & Dohme LLC
HIV Infection
09/21
11/24
MK-8591A-020, NCT04233879 / 2019-000590-23: Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Active, not recruiting
3
599
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir, BIC/FTC/TAF, Bictegravir/emtricitabine/tenofovir alafenamide, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Merck Sharp & Dohme LLC
HIV-1 Infection
11/22
03/25
MK-8591A-019, NCT04233216 / 2019-000588-26: Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Completed
3
35
Europe, Canada, Japan, US, RoW
ISL, Islatravir, MK-8591, DOR, Doravirine, MK-1439, DOR/ISL, Doravirine/Islatravir, MK-8591A, Placebo to ISL, Placebo to DOR
Merck Sharp & Dohme LLC
HIV-1 Infection
11/22
11/23
MK-8591A-051, NCT05631093: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART)

Active, not recruiting
3
501
Europe, Canada, Japan, US, RoW
ART, DOR/ISL, MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
10/24
10/25
MK-8591A-052, NCT05630755: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Active, not recruiting
3
501
Europe, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Merck Sharp & Dohme LLC
HIV-1 Infection
11/24
10/25
MK-8591A-033, NCT04776252 / 2020-001191-14: Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

Active, not recruiting
3
2000
Europe, Canada, Japan, US, RoW
MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
10/27
10/27
NCT05705349: DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Recruiting
3
500
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF
Merck Sharp & Dohme LLC
HIV-1 Infection
10/25
11/26
MK-8591A-054, NCT05766501: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir
Merck Sharp & Dohme LLC
HIV Infection
01/26
01/26

Download Options